Matching slides 303,780
Current window 206,911-206,940
Pages 10,126
Rows per page 30
Component: Titleclear collectionreset all

Component

206,911-206,940 of 303,780

filter-aware
02
Poster #117Theravance Biopharma | Investor Conference Presentation Deck | 44 slides · Theravance Biopharma
Conference presentation Investor relations 1 hit
03
Theravance Biopharma | Investor Conference Presentation Deck | 44 slidesTheravance Biopharma | Investor Conference Presentation Deck | 44 slides · Theravance Biopharma
Conference presentation Investor relations 1 hit
04
Theravance Biopharma | Investor Conference Presentation Deck | 44 slidesTheravance Biopharma | Investor Conference Presentation Deck | 44 slides · Theravance Biopharma
Conference presentation Investor relations 1 hit
05
Theravance Biopharma | Investor Conference Presentation Deck | 44 slidesTheravance Biopharma | Investor Conference Presentation Deck | 44 slides · Theravance Biopharma
Conference presentation Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
07
The slide uses a biological process diagram to explain the mechanism of action for midodrine and droxidopa in the context of autonomic disorders.Theravance Biopharma | Investor Conference Presentation Deck | 44 slides · Theravance Biopharma
Conference presentation Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
08
Includes a screenshot of a BMC Neurology paper and a bar chart showing subgroup analysis of OHSA scores.Theravance Biopharma | Investor Conference Presentation Deck | 44 slides · Theravance Biopharma
Conference presentation Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
09
The slide uses a biological process diagram to explain how different drugs (agonists, precursors, reuptake inhibitors) affect sympathetic signaling to blood vessels.Theravance Biopharma | Investor Conference Presentation Deck | 44 slides · Theravance Biopharma
Conference presentation Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
10
The slide uses a biological process diagram to explain the drug's mechanism of action.Theravance Biopharma | Investor Conference Presentation Deck | 44 slides · Theravance Biopharma
Conference presentation Investor relations Beat · Solution (Provide relief)1 hit
11
The slide uses a process flow diagram to show how patients transition from Study 0169 to 0170.Theravance Biopharma | Investor Conference Presentation Deck | 44 slides · Theravance Biopharma
Conference presentation Investor relations Beat · Solution (Provide relief)1 hit
12
The slide shows a significant increase in Norepinephrine levels with Ampreloxetine treatment compared to placebo.Theravance Biopharma | Investor Conference Presentation Deck | 44 slides · Theravance Biopharma
Conference presentation Investor relations Beat · Solution (Provide relief)1 hit
13
Study 0169 data showing significant increases in Norepinephrine and decreases in DHPG across three patient cohorts.Theravance Biopharma | Investor Conference Presentation Deck | 44 slides · Theravance Biopharma
Conference presentation Investor relations Beat · Solution (Provide relief)Loop · Aha Moment1 hit
14
The chart illustrates a worsening of blood pressure in the placebo group compared to the treatment group.Theravance Biopharma | Investor Conference Presentation Deck | 44 slides · Theravance Biopharma
Conference presentation Investor relations Beat · Solution (Provide relief)Loop · Before After1 hit
15
The slide uses a bar chart with error bars to show treatment effects. 'Worsening' is indicated by a downward arrow on the right.Theravance Biopharma | Investor Conference Presentation Deck | 44 slides · Theravance Biopharma
Conference presentation Investor relations Beat · Solution (Provide relief)Loop · Before After1 hit
16
Includes a footer with abbreviations for BP, DHPG, MSA, NE, and nOH.Theravance Biopharma | Investor Conference Presentation Deck | 44 slides · Theravance Biopharma
Conference presentation Investor relations Beat · Solution (Provide relief)1 hit
17
Poster #106Theravance Biopharma | Investor Conference Presentation Deck | 44 slides · Theravance Biopharma
Conference presentation Investor relations 1 hit
18
Theravance Biopharma | Investor Conference Presentation Deck | 44 slidesTheravance Biopharma | Investor Conference Presentation Deck | 44 slides · Theravance Biopharma
Conference presentation Investor relations 1 hit
19
The slide highlights the failure of Study 0169 and the subsequent early termination of Study 0170.Theravance Biopharma | Investor Conference Presentation Deck | 44 slides · Theravance Biopharma
Conference presentation Investor relations 1 hit
20
The slide outlines a complex clinical trial structure involving rollovers from Study 0169 and de novo participants, leading into a randomized withdrawal period.Theravance Biopharma | Investor Conference Presentation Deck | 44 slides · Theravance Biopharma
Conference presentation Investor relations 1 hit
21
The slide uses a flow diagram to illustrate study design and participant disposition.Theravance Biopharma | Investor Conference Presentation Deck | 44 slides · Theravance Biopharma
Conference presentation Investor relations 1 hit
25
Uses a visual comparison to explain the biological mechanism of action.Theravance Biopharma | Investor Conference Presentation Deck | 44 slides · Theravance Biopharma
Conference presentation Investor relations 1 hit
29
The slide includes a list of authors for a related longitudinal analysis.Theravance Biopharma | Investor Conference Presentation Deck | 44 slides · Theravance Biopharma
Conference presentation Investor relations 1 hit
30
Poster #4Theravance Biopharma | Investor Conference Presentation Deck | 44 slides · Theravance Biopharma
Conference presentation Investor relations 1 hit
31
Theravance Biopharma | Investor Conference Presentation Deck | 44 slidesTheravance Biopharma | Investor Conference Presentation Deck | 44 slides · Theravance Biopharma
Conference presentation Investor relations 1 hit
32
The slide uses a bulleted list to frame the clinical trial narrative from failure to a focused subgroup opportunity.Theravance Biopharma | Investor Conference Presentation Deck | 44 slides · Theravance Biopharma
Conference presentation Investor relations 1 hit
33
The slide uses a biological mechanism diagram to illustrate the drug's effect on norepinephrine reuptake.Theravance Biopharma | Investor Conference Presentation Deck | 44 slides · Theravance Biopharma
Conference presentation Investor relations 1 hit
34
The slide outlines a clinical trial program involving three studies (0169, 0170, 0171) with specific eligibility criteria and endpoints for a longitudinal analysis.Theravance Biopharma | Investor Conference Presentation Deck | 44 slides · Theravance Biopharma
Conference presentation Investor relations 1 hit
35
The diagram tracks patient enrollment, completion, and reasons for discontinuation at each stage.Theravance Biopharma | Investor Conference Presentation Deck | 44 slides · Theravance Biopharma
Conference presentation Investor relations 1 hit
36
The diagram uses a standard CONSORT-style flow chart structure to track patient enrollment, completion, and withdrawal reasons.Theravance Biopharma | Investor Conference Presentation Deck | 44 slides · Theravance Biopharma
Conference presentation Investor relations 1 hit
38
The chart uses a split-axis design to represent different study periods (Study 0169 and 0170).Theravance Biopharma | Investor Conference Presentation Deck | 44 slides · Theravance Biopharma
Conference presentation Investor relations 1 hit
39
The chart uses a split-axis design to represent three distinct study phases (0169, 0170 OL, 0170 RW).Theravance Biopharma | Investor Conference Presentation Deck | 44 slides · Theravance Biopharma
Conference presentation Investor relations 1 hit